araag2/HINT huggingface dataset:
Clinical trial NCT00717990 (phase 2, status: terminated)
Conditions: metastatic colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: capecitabine, bevacizumab, irinotecan
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O
Reason stopped: 
    poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed locally advanced or metastatic colorectal cancer

          -  Measurable or evaluable disease according to the Response Evaluation Criteria in Solid
             Tumors

          -  ECOG performance status ≤ 2

          -  Age 18 - 72 years

          -  Patients who progress after 1st line therapy with FOLFOX/AVASTIN

          -  Adequate liver (Bilirubin ≤ 1.5 upper normal limit, SGOT/SGPT ≤ 4 upper normal limit,
             ALP ≤ 2.5 upper normal limit) renal (Creatinine ≤ 1.5 upper normal limit) and bone
             marrow (ANC ≥ 1,500/mm3, PLT ≥100,000/mm3) function

          -  Patients must be able to understand the nature of this study

          -  Written informed consent

        Exclusion Criteria:

          -  History of serious cardiac disease (unstable angina, congestive heart
             failure,uncontrolled cardiac arrhythmias)

          -  History of myocardial infarction or stroke within 6 months

          -  Clinically significant peripheral vascular disease

          -  History of abdominal fistula, gastrointestinal perforation or intraabdominal abscess
             within 28 days prior to Day 0

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 30 days
             prior to Day 1

          -  Presence of central nervous system or brain metastasis

          -  Evidence of bleeding diathesis or coagulopathy

          -  Blood pressure > 150/100 mmHg

          -  Pregnant or lactating woman

          -  Life expectancy < 3 months

          -  Previous radiotherapy within the last 4 weeks or > 25% of bone marrow

          -  Metastatic infiltration of the liver > 50%

          -  Patients with chronic diarrhea (at least for 3 months) or partial bowel obstruction or
             total colectomy

          -  Active infection requiring antibiotics on Day 1

          -  Second primary malignancy, except for non-melanoma skin cancer and in situ cervical
             cancer

          -  Psychiatric illness or social situation that would preclude study compliance
Clinical trial NCT01149681 (phase 2, status: completed)
Conditions: myelofibrosis
ICD codes: D75.81, C94.41, C94.42, C94.40
Drugs: aplidin (plitidepsin)
SMILES: [H][C@@]12CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)C(=O)[C@@H](OC(=O)C[C@H](O)[C@]([H])(NC(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]1CCCN1C(=O)C(C)=O)[C@@H](C)OC(=O)[C@H](CC1=CC=C(OC)C=C1)N(C)C2=O)[C@@H](C)CC)C(C)C
Eligibility criteria:

        Inclusion Criteria:

          1. Diagnosis of Primary Myelofibrosis (PMF) or Post Polycythemia Vera/Essential
             Thrombocythemia Myelofibrosis(post-ET/PV MF) as per revised World Health Organization
             (WHO) criteria.

          2. High-risk or intermediate-2 risk Myelofibrosis (MF) as defined by the International
             Prognostic Scoring System (IPSS); or intermediate-I risk MF associated with
             symptomatic splenomegaly/hepatomegaly and/or unresponsive to available therapy.

          3. At least 18 years of age, with life expectancy of ≥12 weeks.

          4. Able to provide informed consent and being willing to sign an informed consent form
             (ICF).

          5. Eastern Cooperative Oncology Group (ECOG) performance status ≤2.

          6. Evidence of acceptable organ function within seven days of initiating study drug

        Exclusion Criteria:

          1. Previous treatment with plitidepsin.

          2. Any of the following therapies within two weeks prior to initiation of study drug:

               -  chemotherapy (e.g., hydroxyurea),

               -  immunomodulatory drug therapy (e.g., thalidomide),

               -  immunosuppressive therapy,

               -  corticosteroids >10 mg/day prednisone or equivalent, or

               -  erythropoietin.

          3. Incomplete recovery from major surgery within four weeks of study entry.

          4. Radiation therapy within four weeks of study entry.

          5. Women of childbearing potential

          6. Women who are pregnant or are currently breastfeeding.

          7. Myopathy grade > 2

          8. Known positive status for human immunodeficiency virus (HIV).

          9. Active hepatitis B or C virus (HBV or HCV) infection

         10. Diagnosis of another invasive malignancy

         11. Any acute active infection.

         12. Known hypersensitivity to the study drug or any of its formulation components (e.g.,
             Cremophor®).

         13. Treatment with any investigational product in the 30 days before inclusion in the
             study.
Clinical trial NCT01693315 (phase 2, status: completed)
Conditions: glaucoma, ocular hypertension, eye disease
ICD codes: H40.9, Q15.0, B73.02, H40.823, H40.89, H44.513, H40.821, H40.053, H40.051, H40.052, H40.059
Drugs: ama0076, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria include:

          1. Adults 30-85 years of age

          2. Diagnosis of either ocular hypertension or primary open-angle glaucoma in both eyes

          3. Not receiving medication for IOP, or able to stop such medication for a washout period
             and the duration of the study without significant risk of adverse consequences related
             to glaucomatous disease

          4. Elevated IOP (≥ 24 and ≤ 34 mm Hg at 8 AM and ≥ 21 and ≤ 34 mm Hg at 10 AM on
             Screening Two visit and Baseline visit in one or both eyes off treatment

        Exclusion Criteria include:

          1. Uncontrolled intraocular hypertension defined as >34 mm Hg at either of the
             screening/baseline visits (after a washout phase in those subjects who were currently
             receiving ocular hypotensive therapy).

          2. Receiving more than one medication for IOP at time of screening.

          3. Central corneal thickness of less than 500 µm or greater than 620 µm.

          4. BCVA worse than 20/200 in either eye

          5. Significant visual field loss (ie, mean deviation > 10 db or field loss within 10
             degrees of fixation), a new field defect, or progression of an existing field defect
             in either eye during the year preceding the study.

          6. Acute angle-closure glaucoma or appositional or very narrow anterior chamber angle in
             either eye.
Clinical trial NCT01301820 (phase 2, status: completed)
Conditions: acute myeloid leukemia
ICD codes: C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60
Drugs: azacitidine, lenalidomide
SMILES: NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Cytologically or histologically confirmed acute myeloid leukemia (AML) with :

               -  At least 60 years of age and fit for intensive chemotherapy: PS <2 (ECOG)

               -  Absence of significant co-morbidities

               -  Less than 75 years* of age

               -  LAM with high risk features (blasts > 20% in bone marrow)

               -  Poor risk cytogenetics

               -  Life expectancy > 1 month

               -  Affiliated to social security regimen

               -  No granulocytic sarcoma as sole site of disease

               -  Able and willing to provide written and signed informed consent

        Exclusion Criteria:

          -  Total bilirubin > 2 times upper limit of normal

          -  AST and ALT and/or alkaline phosphatase > 4 times upper limit of normal if not in
             relation with AML.

          -  Factor V < 50% without DIC (Disseminated Intravascular Coagulation)

          -  NYHA class III or IV congestive heart failure (Echo < 40%, LVEF < 50%),Unstable angina
             pectoris, Serious cardiac arrhythmia

          -  Renal failure not related to AML: serum creatinin > 170 μmol/L or clearance of
             creatinin ≤ 50 mL/mn

          -  Known HIV 1- HIV 2 positivity

          -  Prior therapy with azacitidine or lenalidomide

          -  Psychiatric illness or social situations that would preclude compliance with study
             requirements

          -  Uncontrolled infection

          -  Urgent chemotherapy for DIC, spontaneous tumoral lyse syndrome, leucostase without
             cytogentic results

          -  Women who are pregnant or breastfeeding

          -  Women who are unwilling or unable to use an acceptable contraceptive method to avoid
             pregnancy

          -  Men who are unwilling or unable to use an acceptable method of birth control
Clinical trial NCT00448305 (phase 2, status: completed)
Conditions: breast neoplasms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: endotag-1 + paclitaxel, endotag-1, paclitaxel
SMILES: [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically proven triple-receptor-negative metastatic or relapsed breast cancer

          -  Minimum interval of 6 months after the end of any previous taxane- containing
             chemotherapy regimen

          -  At least one tumor lesion measurable according to RECIST criteria

          -  Gender: female

          -  Age >= 18 years old

          -  Negative pregnancy test (females of childbearing potential)

          -  Willingness to perform double-barrier-contraception during study and for 6 months post
             chemotherapy treatment

          -  ECOG performance status 0, 1 or 2

          -  Signed informed consent

        Exclusion Criteria:

          -  More than 1 previous chemotherapeutic treatment for metastatic or relapsed disease

          -  Major surgery < 4 weeks prior to enrollment

          -  Immunotherapy < 2 weeks prior to enrollment

          -  Severe pulmonary obstructive or restrictive disease

          -  Uncontrolled inflammatory disease (autoimmune or infectious)

          -  Clinically significant cardiac disease (NYHA stadium > 2)

          -  Laboratory tests (hematology, chemistry) outside specified limits

          -  Pregnancy or nursing status

          -  Known positive HIV testing

          -  Known hypersensitivity to any component of the EndoTAG-1 or taxane formulations

          -  History of malignancy other than breast cancer < 5 years prior to enrollment, except
             skin cancer (i.e. basal or squamous cell carcinoma) treated locally

          -  Known progressive cerebral metastasis (patients with cerebral metastases in a stable
             state or after successful surgical or radiological treatment are allowed to
             participate in the study)

          -  History of active or significant neurological disorder or psychiatric disorder that
             would prohibit the understanding and giving of informed consent, or would interfere in
             the clinical and radiological evaluation of central nervous system during the trial

          -  Concurrent treatment with other experimental drugs. Participation in another clinical
             trial with any investigational not marketed drug within 30 days prior to study entry
Clinical trial NCT00522145 (phase 2, status: completed)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: xl647
SMILES: COC1=C(OC[C@H]2C[C@H]3CN(C)C[C@H]3C2)C=C2N=CN=C(NC3=CC=C(Cl)C(Cl)=C3F)C2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed diagnosis of unresectable Stage IIIB or Stage IV relapsed or
             recurrent NSCLC.

          -  Subjects must have:

               1. documented (radiological or clinical) progressive disease (PD) following a prior
                  response (including stable disease) to monotherapy with erlotinib or gefitinib
                  that was administered for at least 12 weeks prior to progression OR

               2. a documented T790M EGFR mutation

          -  Measurable disease defined according to RECIST

          -  ECOG performance status of 0 or 1.

          -  Sexually active subjects must use an accepted method of contraception during the
             course of the study.

          -  Female subjects of childbearing potential must have a negative pregnancy test at
             enrollment.

        Exclusion Criteria:

          -  Received radiation to ≥25% of his or her bone marrow within 30 days of XL647
             treatment.

          -  Received erlotinib or gefitinib, or other anticancer therapy within 14 days of the
             first dose of study drug.

          -  Received an investigational drug (excluding erlotinib or gefitinib) within 30 days of
             the first dose of study drug.

          -  Receiving anticoagulation therapy with warfarin.

          -  Not recovered to Grade ≤1 from adverse events (AEs) due to antineoplastic agents,
             investigational drugs, or other medications that were administered prior to study
             enrollment.

          -  Corrected QT interval (QTc) of >0.45 seconds.

          -  Progressive, symptomatic, or hemorrhagic brain or leptomeningeal metastases.

          -  Requires steroid or anticonvulsant therapy for the treatment of brain metastases.
Clinical trial NCT00690443 (phase 2, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: atorvastatin, aegr-733
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C2=C(C=CC=C2)C2=CC=C(C=C2)C(F)(F)F)C2=CC=CC=C2C2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  M/F 18-70

          -  0-1 risk factor, mean LDL-C -/> 160 and -/< 250 mg/dL (Visit 2 & 3)

          -  2+ risk factors, mean LDL-C -/> 130 & -/< 250 mg/dL (Visit 2 & 3)

          -  Fasting mean TGs -/< 400 mg/dL

          -  Understanding and compliance of protocol

          -  sign consent

        Exclusion Criteria:

          -  Females pregnant, lactating, or CBP who have not been using acceptable contraceptive
             methods over previous 3 months

          -  Uncontrolled hypertension >180/95 at screening

          -  Hx of chronic renal insufficiency (serum creatinine > 2.5 mg/dL)

          -  Hx of liver disease or transaminases > 1.5 X ULN

          -  Positive for Hepatitis B or C

          -  Major surgery within past 3 mos

          -  Cardiac insufficiency defined as functional Class II-Class IV

          -  Hx of malignancy within previous 5 years

          -  Participation in another investigational drug study within past 6 wks

          -  Serious or unstable medical or psychological condition

          -  Regular alcohol use > 1 drink per day

          -  Regular consumers of grapefruit juice or medications known to be metabolized by CYP
             3A4

          -  Use of other lipid-lowering meds (washout permitted)

          -  Acute CVD

          -  Diabetes Mellitus

          -  Fasting glucose >110 mg/dL

          -  BMI -/> 40 kg/m2

          -  Significant gastrointestinal symptoms such as IBS

          -  Use of fish oils, niacin, herbal wt. loss products (washout permitted)
Clinical trial NCT01483599 (phase 2, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: cnto 1959 (5 mg), cnto 1959 (15 mg), cnto 1959 (50 mg), cnto 1959 (100 mg), cnto 1959 (200 mg), adalimumab, placebo
SMILES: O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of plaque-type psoriasis with or without psoriatic arthritis for at least 6
             months prior to first administration of any study agent

          -  Must be a candidate for phototherapy or systemic treatment for psoriasis (either new
             to treatment or having had previous treatment)

          -  Must be considered, in the opinion of the investigator, suitable candidates for
             adalimumab therapy

          -  If a woman, she must be postmenopausal, or if premenopausal, she must be either
             surgically sterile, practicing a highly effective method of birth control, or not
             heterosexually active during the study and for 5 months after receiving the last dose
             of study drug

          -  If a man, he must agree to use a double-barrier method of birth control (or must have
             been surgically sterilized) and to not donate sperm during the study and for 5 months
             after receiving the last dose of study drug.

        Exclusion Criteria:

          -  History of or current signs or symptoms of severe, progressive, or uncontrolled renal,
             hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic,
             cerebral, or psychiatric disease

          -  Has a contra-indication to anti-TNF therapy

          -  Has a history of chronic or recurrent infectious disease

          -  Has a nonplaque form of psoriasis or has drug-induced psoriasis

          -  Has been previously treated with adalimumab

          -  Has received any therapeutic agent directly targeted to IL-12, IL-17, or IL-23,
             (including but not limited to ustekinumab, briakinumab [ABT-874], AIN457, and
             SCH900222) within 6 months of the first administration of study agent.
Clinical trial NCT00461708 (phase 2, status: completed)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: erlotinib, gemcitabine
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, >=18 years of age;

          -  locally advanced and/or metastatic pancreatic cancer (stage III or IV);

          -  Karnofsky performance Status of >=60%.

        Exclusion Criteria:

          -  local(stage IA to IIB) pancreatic cancer;

          -  <=6 months since last adjuvant chemotherapy;

          -  previous systemic therapy for metastatic pancreatic cancer;

          -  other primary tumor within last 5 years (except for adequately treated cancer in situ
             of cervix, or basal cell skin cancer);

          -  clinically significant cardiovascular disease.
Clinical trial NCT00205322 (phase 2, status: completed)
Conditions: metastatic colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: chemotherapy (capecitabine, oxaliplatin, 5-fu, leucovorin)
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  no prior treatment for metastatic disease

          -  PS 0-2

          -  measurable disease

        Exclusion Criteria:

          -  neuropathy > or equal to grade 2

          -  concomitant radiation therapy or other systemic cancer therapies

          -  brain mets
Clinical trial NCT01373151 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: bms-945429 placebo, methotrexate, methotrexate, methotrexate placebo, methotrexate, adalimumab placebo, adalimumab
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, O, O
Eligibility criteria:

        Inclusion Criteria:

          -  Inadequate response to Methotrexate

          -  Must have been taking Methotrexate for at least 3 months at a minimal weekly dose of
             at least 15 mg and stable dose for 4 weeks prior to randomization

          -  American College of Rheumatology (ACR) global function status class 1-3

          -  Minimum of 6 swollen and 6 tender joints with evidence of synovitis in at least 1 hand
             or wrist

          -  High sensitivity C-reactive protein (hsCRP) ≥ 0.8 mg/dL

        Exclusion Criteria:

          -  Previously received or currently receiving concomitant biologic therapy
Clinical trial NCT01384734 (phase 2, status: completed)
Conditions: infection, human immunodeficiency virus
ICD codes: Z21
Drugs: bms-663068 400 mg, bms-663068 800 mg, bms-663068 600 mg, bms-663068 1200 mg, raltegravir 400 mg, tenofovir 300 mg, ritonavir 100 mg, atazanavir 300 mg
SMILES: COC1=C2C(=CN(COP(O)(O)=O)C2=C(N=C1)N1C=NC(C)=N1)C(=O)C(=O)N1CCN(CC1)C(=O)C1=CC=CC=C1, COC1=C2C(=CN(COP(O)(O)=O)C2=C(N=C1)N1C=NC(C)=N1)C(=O)C(=O)N1CCN(CC1)C(=O)C1=CC=CC=C1, COC1=C2C(=CN(COP(O)(O)=O)C2=C(N=C1)N1C=NC(C)=N1)C(=O)C(=O)N1CCN(CC1)C(=O)C1=CC=CC=C1, COC1=C2C(=CN(COP(O)(O)=O)C2=C(N=C1)N1C=NC(C)=N1)C(=O)C(=O)N1CCN(CC1)C(=O)C1=CC=CC=C1, CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1, C[C@H](CN1C=NC2=C1N=CN=C2N)OCP(O)(O)=O, CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Plasma HIV-1 RNA ≥ 1000 copies/ml at Screening

          -  Treatment experience with antiretroviral therapies (excluding integrase inhibitors)

          -  Screening PHENOSENSE Entry indicating BMS-626529 inhibitory concentration (IC)50 < 0.1
             μM

          -  Cluster of differentiation (CD)4+ T-cell count > 50 cells/mm3

        Exclusion Criteria:

          -  History (or evidence at Screening) of genotypic resistance to any component of the
             study regimen [ Tenofovir Disoproxil Fumarate (TDF), Atazanavir (ATV), Raltegravir
             (RAL)]

          -  Certain laboratory and electrocardiogram (ECG) values
Clinical trial NCT00642018 (phase 2, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: docetaxel, ly2181308 sodium, prednisone
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate which is
             metastatic and/or unresectable

          -  Hormone refractory prostate cancer defined as progressive based by documented 2
             increase Prostate specific antigen (PSA) values over a previous reference value.

          -  Eastern Cooperative Oncology Group (ECOG) status 0-2

          -  Adequate hematological functions, liver and renal functions

        Exclusion Criteria:

          -  Known hypersensitivity to docetaxel or taxane therapy

          -  Documented central nervous system or leptomeningeal metastasis at time of study entry

          -  Had prior treatment with chemotherapy, bone-seeking radionuclides in past 6 weeks
             prior to enrollment, or radiotherapy involving more than 25% of marrow producing area.

          -  Evidence of painful and/or destructive bone metastases for which radiation therapy,
             bisphosphonates or bone-seeking radionuclides are necessary.

          -  Have received treatment in the last 30 day with a drug which has not received
             regulatory approval for any indication at the time of study entry.